Gland Pharma Limited Business Intelligence Report
Gland Pharma Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Gland Pharma is a leading B2B injectable-focused pharmaceutical company, controlled by Shanghai Fosun Pharma. Over the last decade, it has leveraged a complex manufacturing moat to serve global markets, particularly the US. While the company maintained industry-leading margins of 34-38% in the early 2020s, recent years have seen compression due to specialized acquisition costs and pricing pressure. The company remains almost debt-free with a robust balance sheet, though recent growth has shifted from organic excellence to a mix of acquisition-led expansion (Cenexi). Despite a temporary dip in…
Key Changes in FY2026
Gland Pharma has evolved from a liquid parenteral manufacturer in 1978 to a global complex injectables leader with a presence in over 60 countries. The timeline shows a clear transition from a B2B volume player to a high-value complex molecule developer, evidenced by the launch of 85 new molecules between FY22 and FY24. Strategic expansion into the US market has been the primary growth engine, recently bolstered by entries into oncology and ophthalmic solutions. The acquisition of Cenexi represents the latest evolution into the European CDMO space, diversifying the geographic revenue mix and reducing dependency on the US market. The business is consistently moving up the value chain, shifting from simple ampoules to pre-filled syringes (PFS) and lyophilized products with higher entry…
Management Commentary
Management is viewed as technically competent but faces scrutiny regarding the influence of its parent, Fosun Pharma. Transparency in MD&A is generally high regarding product launches and FDA approvals, though explanations for margin contraction could be more granular. The leadership has successfully navigated numerous US FDA inspections, which is a critical success factor in the injectable space. The business evolution toward complex molecules and CDMO services shows a forward-looking vision. However, the 6% reduction in promoter holding over the last 3 years and recent directorial resignations are monitorables. The management alignment is considered acceptable but closely tied to the parent company's global strategy.
Financial Highlights
Revenue grew at a 13% CAGR over the last 5 years, though PAT growth lagged at 1% due to recent margin erosion. Operating margins peaked at 38% in FY21 but declined to 25% by FY26 estimates as the product mix shifted and competition intensified. The impact of the Cenexi acquisition is visible in the doubling of fixed assets and increased depreciation. PBT margins remain healthy compared to peers, but the trend has been downward over the last three fiscal cycles. Inventory days remain high (average >250), reflecting the long lead times and complexity of sterile injectable manufacturing and supply chain management.
Major Opportunities
- Almost debt-free balance sheet
- Robust FCF generation consistency
- High ROCE relative to industry median
Major Risks
- Operating margins declining significantly
- Low ROE of 9% over last 3 years
- Promoter holding reduction of 6%
About Gland Pharma Limited's Annual Report & Financial Performance
The latest Gland Pharma Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Gland Pharma Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Gland Pharma Limited — Frequently Asked Questions
Explore more Gland Pharma Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.